A research group at the Department of Microbiology, Swedish University of Agricultural Sciences (SLU) in Uppsala, Sweden has – in collaboration with J-I Flock’s research group at the Karolinska Institutet medical university in Stockholm, the pharmacological company Intervacc AB, Stockholm and the Animal Health Trust in the UK – after many years of research made a breakthrough in finding a vaccine against the horse disease strangles.
Strangles is a most contagious disease caused by the bacteria Streptococcus equi. The disease results in high fever and characteristically swollen lymphoid glands in the neck region generating large boils that often burst. Most contaminated horses recover and become immune against the disease, but in worst cases strangles can be fatal. A stable where strangles has been discovered must be put in quarantine causing economical losses and practical problems. The disease is spread worldwide; in Sweden some 100 cases are reported annually, in the UK circa 1,000 cases per year are reported.
Today there exists no safe and efficient vaccine against strangles, and previous vaccines are based on live bacteria, which is hazardous and may cause severe side effects. The new vaccine is based on pure proteins produced by recombinant DNA technology. The vaccine consists of seven different Streptococcus proteins, and the results from injecting horses have been most positive so far, i.e. the vaccine is highly protective and has shown no side effects.
The goal is to have the new strangles vaccine commercially available in a near future. The research results also imply a possibility to develop protein-based vaccines against other Streptococcus infections in animals as well as humans, e.g. tonsillitis.
- Guss et al. Getting to Grips with Strangles: An Effective Multi-Component Recombinant Vaccine for the Protection of Horses from Streptococcus equi Infection. PLoS Pathogens, 2009; 5 (9): e1000584 DOI: 10.1371/journal.ppat.1000584
Cite This Page: